Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Department of Surgery, University of California San Francisco, San Francisco, California, USA.
Thyroid. 2022 Apr;32(4):397-410. doi: 10.1089/thy.2021.0557. Epub 2022 Mar 15.
In response to evidence of overdiagnosis and overtreatment of papillary thyroid carcinoma (PTC), the 2009 and 2015 American Thyroid Association (ATA) adult guidelines recommended less extensive surgery (lobectomy vs. total thyroidectomy) and more restricted use of postsurgical radioactive iodine (RAI) in management of PTC at low risk of recurrence. In 2015, active surveillance was suggested as a viable option for some <1-cm PTCs, or microcarcinomas. The 2015 ATA pediatric guidelines similarly shifted toward more restricted use of RAI for low-risk PTCs. The impact of these recommendations on low-risk adult and pediatric PTC management remains unclear, particularly after 2015. Using data from 18 Surveillance, Epidemiology, and End Results (SEER) U.S. registries (2000-2018), we described time trends in reported first-course treatment (total thyroidectomy alone, total thyroidectomy+RAI, lobectomy, no surgery, and other/unknown) for 105,483 patients diagnosed with first primary localized PTC (without nodal/distant metastases), overall and by demographic and tumor characteristics. The declining use of RAI represented the most pronounced change in management of PTCs <4 cm (44-18% during the period 2006-2018), including microcarcinomas (26-6% during the period 2007-2018). In parallel, an increasing proportion of PTCs were managed with total thyroidectomy alone (35-54% during the period 2000-2018), while more subtle changes were observed for lobectomy (declining from 23% to 17% during the period 2000-2006, stabilizing, and then rising from 17% to 24% during the period 2015-2018). Use of nonsurgical management did not meaningfully change over time, impacting <1% of microcarcinomas annually during the period 2000-2018. Similar treatment trends were observed by sex, age, race/ethnicity, metropolitan vs. nonmetropolitan residence, and insurance status. For pediatric patients (<20 years), use of RAI peaked in 2009 (59%), then decreased markedly to 11% (2018), while use of total thyroidectomy alone and, to a lesser extent, lobectomy increased. No changing treatment trends were observed for ≥4-cm PTCs. The declining use of RAI in management of low-risk adult and pediatric PTC is consistent with changing recommendations from the ATA practice guidelines. Post-2015 trends in use of lobectomy and nonsurgical management of low-risk PTCs, particularly microcarcinomas, were more subtle than expected; however, these trends may change as evidence regarding their safety continues to emerge.
针对甲状腺乳头癌(PTC)过度诊断和过度治疗的证据,2009 年和 2015 年美国甲状腺协会(ATA)成人指南建议在管理低复发风险的 PTC 时进行范围较小的手术(甲状腺叶切除术与甲状腺全切除术)和更严格地使用术后放射性碘(RAI)。2015 年,主动监测被建议作为某些<1 厘米 PTC 或微癌的可行选择。2015 年 ATA 儿科指南同样倾向于在低风险 PTC 中更严格地使用 RAI。这些建议对低风险成人和儿科 PTC 管理的影响仍不清楚,特别是在 2015 年之后。利用来自 18 个监测、流行病学和最终结果(SEER)美国登记处(2000-2018 年)的数据,我们描述了<4 厘米的报告首次治疗(单独甲状腺全切除术、甲状腺全切除术+RAI、甲状腺叶切除术、无手术和其他/未知)的时间趋势,用于诊断为<4 厘米的 105483 例局部原发性 PTC(无淋巴结/远处转移),包括微癌(2007-2018 年期间为 26-6%),按人口统计学和肿瘤特征进行分类。RAI 的使用减少是 PTC<4 厘米(2006-2018 年期间为 44-18%)管理中最明显的变化,包括微癌(2007-2018 年期间为 26-6%)。同时,单独使用甲状腺全切除术治疗 PTC 的比例增加(2000-2018 年期间为 35-54%),而甲状腺叶切除术的变化则较为微妙(2000-2006 年期间下降至 23%,稳定,然后在 2015-2018 年期间上升至 24%)。非手术管理的使用并没有随着时间的推移而显著变化,在 2000-2018 年期间,每年<1%的微癌采用这种方法。按性别、年龄、种族/民族、大都市与非大都市居住、保险状况观察到类似的治疗趋势。对于儿科患者(<20 岁),RAI 的使用在 2009 年达到高峰(59%),然后显著下降至 11%(2018 年),而单独使用甲状腺全切除术和甲状腺叶切除术的使用有所增加。≥4 厘米的 PTC 未观察到治疗趋势的变化。低风险成人和儿科 PTC 管理中 RAI 使用的减少与 ATA 实践指南的不断变化的建议是一致的。2015 年后,低风险 PTC,特别是微癌,甲状腺叶切除术和非手术治疗的使用趋势较为微妙,但是随着有关其安全性的证据不断出现,这些趋势可能会发生变化。
Front Endocrinol (Lausanne). 2022
JAMA Otolaryngol Head Neck Surg. 2022-12-1
Laryngoscope Investig Otolaryngol. 2025-6-24
Ann Surg Oncol. 2025-5
JAMA Otolaryngol Head Neck Surg. 2024-11-7
Front Endocrinol (Lausanne). 2024
Endocr Pract. 2021-12
JAMA Otolaryngol Head Neck Surg. 2021-7-1
J Clin Endocrinol Metab. 2021-5-13